Psychedelic Medicine Collaborative
Psychedelic Medicine Collaborative · Founded 2026

The industry needs a
unified voice.
Now more than ever.

Psychedelic medicine is at a historic inflection point. The regulatory environment is shifting, public attention is intense, and the path forward is genuinely uncertain. This collaborative exists to ensure the industry navigates that path together — not in isolation.

Express Interest Learn More ↓
Scroll
Our Mission

Forging collective leadership for a field at a crossroads

Psychedelic medicine is advancing into mainstream healthcare at a pace that the surrounding ecosystem — regulatory frameworks, payer policies, workforce infrastructure, and public trust — has not kept up with. No single company can address those gaps on its own.

The Psychedelic Medicine Collaborative was created to fill that gap. It is a global forum for pharmaceutical companies, researchers, healthcare providers, and patient advocates to build the shared infrastructure this field needs: credible representation with regulators across jurisdictions, evidence-based standards for delivery and reimbursement, and a responsible public narrative that reflects both the promise and the complexity of psychedelic-assisted therapies.

This Collaborative will help shape the norms, standards, and policies that govern this field for years to come.

Priority Issues

Four challenges the Collaborative was built to address

Priority 01
Regulatory pathway clarity
There is no established regulatory playbook for psychedelic-assisted therapies in any major market. In the United States, controlled substance scheduling, clinical setting requirements, prescriber training standards, and REMS program design are all challenges. Beyond U.S. borders, the EMA, MHRA, PMDA and others are navigating the same questions independently. The Collaborative engages regulatory bodies across jurisdictions to help build workable, science-based frameworks and to prevent companies from being forced to navigate divergent pathways alone.
Priority 02
Public narrative and trust
Media coverage of psychedelic medicine ranges from breathless enthusiasm to moral panic. The field needs a consistent, credible, evidence-based narrative — and a responsible voice that the press and public can engage with. No single company can be that voice without appearing self-interested. The Collaborative will produce shared communications, fact sheets, and messaging frameworks that give the whole field a grounded, consistent story to tell.
Priority 03
Reimbursement and payer readiness
The reimbursement landscape remains uncertain. Commercial insurers are already preparing for integration of psychedelic-assisted treatments, with internal task forces evaluating clinical risk and reimbursement feasibility. The payer framework being built now will define patient access for a generation. The Collaborative can develop principles that reflect the real cost and benefit structure of psychedelic therapy.
Priority 04
Healthcare delivery infrastructure
Approvals are coming faster than the healthcare system is prepared for. Post-approval administration will require certified prescribers, trained facilitators present during multi-hour drug administration sessions, and structured post-experience integration protocols. Major healthcare stakeholders including providers, health system administrators, medical societies are now engaged, but the delivery infrastructure to actually train and operationalize the workforce does not yet exist. Without shared standards, approvals will outpace the system’s ability to deliver care safely.
What We Do

How the Collaborative creates value for its members

The Collaborative operates through three interconnected workstreams — each designed to produce outputs that no member organization could develop alone, and that carry more credibility precisely because they represent a collective position.
◈
Thought Leadership & Consensus
The Collaborative develops white papers, policy briefs, and consensus documents that translate emerging clinical evidence into accessible frameworks for payers, regulators, and healthcare systems. Scientific and clinical working groups convene to develop shared positions on contested questions — giving the field a coherent, evidence-grounded voice across all major regulatory environments.
White papers on priority implementation questions
Regulatory comment letters and policy briefs
Consensus statements from cross-sector working groups
Health economic messaging and coverage frameworks
◉
Convenings
The Collaborative brings together member organizations, regulators, payer representatives, clinical leaders, and patient advocates in structured forums designed to build the relationships and shared understanding that make policy progress possible.
Virtual roundtables timed to pre-readout stakeholder alignment
Conference sidecar events at key psychedelic and psychiatry meetings
Standalone forums on treatment standards, access, and safety
Mixed-stakeholder gatherings: clinicians, advocates, payers, patients
◎
Patient Advocacy & Engagement
The Collaborative can engage and elevate the voice of patient advocates in a way no company can do alone. Ensuring the patient experience is known and respected as coverage policies, clinical recommendations and other standards are set is essential to long term success.
Evidence-informed patient and caregiver journey maps
Patient and caregiver activation frameworks
Cross-functional activation priorities for med affairs and advocacy
Lived experience advisory councils and stakeholder validation
Membership

Who should join this collaborative

Membership is not contingent on a shared scientific position or a specific regulatory outcome. It is for organizations that believe a collective voice is more effective than a fragmented one — and that are prepared to help build it.
The Convener

High Lantern Group

High Lantern Group is a strategic communications consultancy that specializes in coalition creation and management, stakeholder strategy, and evidence-to-narrative work across pharma and public policy. We have been building coalitions for 15 years — across global health, aging, antimicrobial resistance, and patient advocacy.

Learn more about HLG →

Ready to explore membership?

The Collaborative is in its founding phase. We are having exploratory conversations now — no commitments required. Reach out to High Lantern Group directly to discuss whether this is right for your organization and what role you would want to play.

Get in Touch Visit highlanterngroup.com
High Lantern Group © 2026 High Lantern Group · Convener of the Psychedelic Medicine Collaborative